课题基金 / 基金详情

GLUTATHIONE AND RESISTANCE TO CANCER CHEMOTHERAPY

GLUTATHIONE AND RESISTANCE TO CANCER CHEMOTHERAPY
谷胱甘肽与癌症化疗耐药性
批准号:
2896386
负责人:
OWEN W GRIFFITH
金额:
$20.42万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-04-01 至 2001-03-31

项目摘要

项目成果

OWEN W GRIFFITH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Applicant's Abstract) Bifunctional alkylating agents (e.g., melphalan, cyclophosphamide, chlorambucil) and platinum antitumor compounds (e.g. cisplatin, carboplatin) are used to treat a wide range of human malignancies. The antitumor activity of such compounds is due to their ability to crosslink chromosomal DNA of rapidly dividing cells thereby preventing tumor cell proliferation and inducing tumor cell death. The therapeutic efficacy of such agents is believed to be reduced by their reaction with glutathione (g-glutamylcysteinylglycine, GSH) a peptide present in all cells including tumor cells. Studies published over the past several years show that the intrinsic or acquired resistance of many tumors to bifunctional alkylating agents or platinum antitumor compounds is associated with elevated levels of GSH in the tumor. To reverse such resistance, tumor-bearing animals have been administered buthionine sulfoximine (BSO), and inhibitor of gamma-glutamylcysteine synthetase (GCS) the enzyme catalyzing the first step in GSH synthesis. In such animals, the ongoing reactions of GSH utilization cause GSH depletion and increased sensitivity to alkylating agents and platinum compounds as well as to radiation therapy. Buthionine sulfoximine is currently undergoing clinical trial as an adjuvant to melphalan chemotherapy. Effective depletion of tumor GSH requires that GSH synthesis be potently and consistently inhibited; the potential rate of GSH synthesis is sufficiently high that even a brief lapse in GCS inhibition can result in substantial repletion of tumor GSH and restoration of resistance. The applicant proposes to develop improved agents for inhibition of GSH synthesis by elucidating the enzymology of GCS and by synthesizing and testing novel inhibitors. Specific aims are as follows (1) The interaction of human GCS with its substrate and known inhibitors will be characterized. (2) Novel analogs of BSO with improved affinity for g-GCS will be synthesized and tested in vitro and in vivo. (3) Novel covalently reactive transition state inhibitors of g-GCS will be synthesized and tested in vitro and in vivo. (4) The ability of novel inhibitors to increase efficacy of melphalan- and cisplatin-based chemotherapy of human ovarian cancer xenografts will be characterized in nude mice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MALDI MASS SPECTROMETER FOR PROTEIN AND PEPTIDE ANALYSIS
  • 批准号:
    6051121
  • 项目类别:
  • 资助金额:
    $24.28万
  • 财政年份:
    2000
  • 负责人:
    OWEN W GRIFFITH
  • 依托单位:
GLUTATHIONE AND RESISTANCE TO CANCER CHEMOTHERAPY
  • 批准号:
    2561048
  • 项目类别:
  • 资助金额:
    $20.07万
  • 财政年份:
    1998
  • 负责人:
    OWEN W GRIFFITH
  • 依托单位:
GLUTATHIONE AND RESISTANCE TO CANCER CHEMOTHERAPY
  • 批准号:
    6173420
  • 项目类别:
  • 资助金额:
    $20.79万
  • 财政年份:
    1998
  • 负责人:
    OWEN W GRIFFITH
  • 依托单位:
NITRIC OXIDE SYNTHASE--ENZYMOLOGY AND METABOLIC ROLE
  • 批准号:
    2148704
  • 项目类别:
  • 资助金额:
    $18.26万
  • 财政年份:
    1995
  • 负责人:
    OWEN W GRIFFITH
  • 依托单位:
海外基金